Expect Questions About Paxlovid or Molnupiravir for COVID-19

You'll hear more about Paxlovid (nirmatrelvir/ritonavir), a new oral antiviral to treat COVID-19...and molnupiravir once it's approved.

Either will be an option for patients with mild to moderate COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.

Be ready to handle these Rxs correctly...and ensure safe use.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote